VG Life Sciences

VG Life Sciences is a biotechnology startup dedicated to developing innovative therapies for drug-resistant cancers and autoimmune diseases. The company's focus on advancing research and development is facilitated by two platform technologies: Targeted Peptide Technology (TPT) and Metabolic Disruption Technology (MDT). The company's flagship drug, VG1177, has shown promising potential, holding a composition-of-matter patent (Patent No: US 8,957,031). VG1177 aims to inhibit the survival of pro-inflammatory cells responsible for autoimmune diseases. Having completed a pre-investigational new drug meeting with the FDA (IND # 110820) and initiated preclinical work in November 2013, VG Life Sciences is making significant strides towards clinical trials. Concurrently, the company is conducting extensive research at the Texas A&M Health Sciences Center laboratory, collaborating with research scientists from various institutions nationwide. In 2013, the company secured a $2.24M Post-IPO Equity investment from MedBridge Venture Fund, underscoring the investor confidence in VG Life Sciences' groundbreaking approach to addressing critical medical challenges. Founded in 1995, VG Life Sciences continues to drive forward in the biotechnology and healthcare industries, poised to make a profound impact with its pioneering drug technologies.